These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6594116)

  • 1. Hypoglycemic episodes during continuous subcutaneous insulin infusion: decreased frequency but increased susceptibility.
    Chisholm DJ; Kraegen EW; Hewett MJ
    Aust N Z J Med; 1984 Jun; 14(3):255-9. PubMed ID: 6594116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy.
    Ng Tang Fui S; Pickup JC; Bending JJ; Collins AC; Keen H; Dalton N
    Diabetes Care; 1986; 9(3):221-7. PubMed ID: 3525052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of improved glycemic control by continuous subcutaneous insulin infusion on hormonal responses to insulin-induced hypoglycemia in type 1 diabetics.
    Lins PE; Clausen N; Adamson U; Kollind M; Hamberger B; Efendic S
    Acta Med Scand; 1985; 218(1):111-8. PubMed ID: 4050545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous subcutaneous insulin infusion in adults: glycemic advantage is predicted by venous plasma C-peptide concentrations.
    Rodger NW; Dupre J; Canny CL; Brown WF
    Diabetes Care; 1985; 8(5):447-55. PubMed ID: 3902423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counterregulatory hormone responses preserved after long-term intravenous insulin infusion compared to continuous subcutaneous insulin infusion.
    Gulan M; Perlman K; Sole M; Albisser AM; Zinman B
    Diabetes; 1988 May; 37(5):526-31. PubMed ID: 3282943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study.
    Giménez M; Lara M; Conget I
    Diabetes Technol Ther; 2010 Jul; 12(7):517-21. PubMed ID: 20597825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of continuous subcutaneous insulin infusion and daily supplemental insulin glargine injection in children with type 1 diabetes.
    Alemzadeh R; Parton EA; Holzum MK
    Diabetes Technol Ther; 2009 Aug; 11(8):481-6. PubMed ID: 19698060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of counterregulatory hormone secretion and symptoms during hypoglycemia in IDDM. Effect of glycemic control.
    Kinsley BT; Widom B; Simonson DC
    Diabetes Care; 1995 Jan; 18(1):17-26. PubMed ID: 7698043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational 7-year study of continuous subcutaneous insulin infusion for the treatment of type 1 diabetes mellitus.
    Papargyri P; Ojeda Rodríguez S; Corrales Hernández JJ; Mories Álvarez MT; Recio Córdova JM; Delgado Gómez M; Sánchez Marcos AI; Iglesias López RA; Herrero Ruiz A; Beaulieu Oriol M; Miralles García JM
    Endocrinol Nutr; 2014 Mar; 61(3):141-6. PubMed ID: 24355548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
    Potti LG; Haines ST
    J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent hypoglycemia impairs glucose counterregulation.
    Widom B; Simonson DC
    Diabetes; 1992 Dec; 41(12):1597-602. PubMed ID: 1446801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy.
    Sahin SB; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
    Acta Diabetol; 2010 Dec; 47(4):325-30. PubMed ID: 20842389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluating the feature of hypoglycemia detected by continuous glucose monitoring system during temporary continuous subcutaneous insulin infusion in type 2 diabetes patients].
    Li M; Zhou J; Bo YQ; Lu W; Jia WP; Xiang KS
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1679-82. PubMed ID: 19024537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study.
    Fresa R; Visalli N; Di Blasi V; Cavallaro V; Ansaldi E; Trifoglio O; Abbruzzese S; Bongiovanni M; Agrusta M; Napoli A
    Diabetes Technol Ther; 2013 Apr; 15(4):328-34. PubMed ID: 23537417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
    Buczkowska EO; Dworzecki T; Wiedermann G; Malanowicz B; Szot D
    Przegl Lek; 2005; 62(1):49-53. PubMed ID: 16053222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.